Q-omics provides the consensus-scored KDM5C profile across patient tissues and cancer cell-line models. KDM5C expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, KDM5C is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, KDM5C protein abundance shows 31,642 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KIRC, and LSCC as cancer lineages where KDM5C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KDM5C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KDM5C survival associations across molecular data types. KDM5C RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KDM5C RNA expression–survival associations across cancer types. High KDM5C expression shows unfavorable associations in MESO, LIHC, ACC, LUSC, LUAD and KICH. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for KDM5C RNA expression.
This table summarizes KDM5C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KDM5C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KDM5C shows higher tumor expression in KIRC, COAD, LIHC, KIRP, STAD and BLCA. The KIRC box plot shows higher KDM5C RNA expression in tumor versus normal tissue (log2 FC = +0.621, t-test p < 0.001).
This table shows molecular features associated with KDM5C in patient tissues and cancer cell lines. In patient samples, KDM5C shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KDM5C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
